Share This Article:

Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer

Abstract Full-Text HTML Download Download as PDF (Size:186KB) PP. 1068-1073
DOI: 10.4236/jct.2013.46121    3,055 Downloads   4,308 Views  

ABSTRACT

Gemcitabine and cisplatin combination therapy (GC) is accepted as a standard treatment for advanced biliary tract cancer (BTC). However, little information is available regarding such treatment in the clinical practice setting in Japan. We retrospectively examined the clinical data of patients with unresectable or recurrent BTC who received GC as first-line treatment. The regimen consisted of cisplatin (25 mg/m2) and gemcitabine (1000 mg/m2) administered intravenously on days 1 and 8 of repeated 3-week cycles. Twenty patients were analyzed. A total of 148 cycles of GC was administered, with a median of 8 and a range of 1 to 18 cycles. Treatment delay and dose reduction were noted in 35 (24%) and 41 (28%) of the 148 cycles, respectively. The major adverse events of grade 3 or 4 included neutropenia (50%), leukopenia (45%), anemia (30%), and thrombocytopenia (15%). Nonhematologic toxicities included nausea (10%), appetite loss (10%), and fatigue (10%). Median progression-free and overall survival times were 6.9 and 12.3 months, respectively. Gallbladder cancer showed a significantly higher response rate than did other types of BTC (chi-squaretest, P = 0.002). GC was thus effective and well tolerated as first-line chemotherapy for Japanese patients with advanced BTC in the clinical practice setting.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

H. Kawakami, I. Okamoto, W. Okamoto, M. Takeda, S. Ueda, T. Kudo, S. Nishina, Y. Fujisaka, M. Miyazaki, J. Tsurutani, T. Kurata and K. Nakagawa, "Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer," Journal of Cancer Therapy, Vol. 4 No. 6, 2013, pp. 1068-1073. doi: 10.4236/jct.2013.46121.

References

[1] G. Randi, M. Malvezzi, F. Levi, J. Ferlay, E. Negri, S. Franceschi and C. La Vecchia, “Epidemiology of Biliary Tract Cancers: An Update,” Annals of Oncology, Vol. 20, No. 1, 2009, pp. 146-159. doi:10.1093/annonc/mdn533
[2] (FPCR) FFPOCR, “Cancer Statistics Update,” Number of Deaths (2008-2009), Cancer Site, 2010. http://www.fpcr.or.jp/pdf/statistics/fig01.pdf
[3] B. Glimelius, K. Hoffman, P. O. Sjoden, G. Jacobsson, H. Sellstrom, L. K. Enander, T. Linne and C. Svensson, “Chemotherapy Improves Survival and Quality of Life in Advanced Pancreatic and Biliary Cancer,” Annals of Oncology, Vol. 7, No. 6, 1996, pp. 593-600. doi:10.1093/oxford journals.annonc.a010676
[4] T. Okusaka, H. Ishii, A. Funakoshi, K. Yamao, S. Ohkawa, S. Saito, H. Saito and T. Tsuyuguchi, “Phase II Study of Single-Agent Gemcitabine in Patients with Advanced Biliary Tract Cancer,” Cancer Chemotherapy and Pharmacology, Vol. 57, No. 5, 2006, pp. 647-653. doi:10.1007/s00280-005-0095-3
[5] S. Kubicka, K. L. Rudolph, M. K. Tietze, M. Lorenz and M. Manns, “Phase II Study of Systemic Gemcitabine Chemotherapy for Advanced Unresectable Hepatobiliary Carcinomas,” Hepato Gastroenterology, Vol. 48, No. 38, 2001, pp. 783-789.
[6] M. H. Lin, J. S. Chen, H. H. Chen and W. C. Su, “A Phase II Trial of Gemcitabine in the Treatment of Advanced Bile Duct and Periampullary Carcinomas,” Chemotherapy, Vol. 49, No. 3, 2003, pp. 154-158. doi:10.1159/000070622
[7] S. T. Kim, J. O. Park, J. Lee, K. T. Lee, J. K. Lee, S. H. Choi, J. S. Heo, Y. S. Park, W. K. Kang and K. Park, “A Phase II Study of Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer,” Cancer, Vol. 106, No. 6, 2006, pp. 1339-1346. doi:10.1002/cncr.21741
[8] B. K. Park, Y. J. Kim, J. Y. Park, S. Bang, S. W. Park, J. B. Chung, K. S. Kim, J. S. Choi, W. J. Lee and S. Y. Song, “Phase II Study of Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer,” Journal of Gastroenterology and Hepatology, Vol. 21, No. 6, 2006, pp. 999-1003. doi:10.1111/j.1440-1746.2006.04230.x
[9] S. Thongprasert, S. Napapan, C. Charoentum and S. Moonprakan, “Phase II Study of Gemcitabine and Cisplatin as First-Line Chemotherapy in Inoperable Biliary Tract Carcinoma,” Annals of Oncology, Vol. 16, No. 2, 2005, pp. 279-281. doi:10.1093/annonc/mdi046
[10] D. C. Doval, J. S. Sekhon, S. K. Gupta, J. Fuloria, V. K. Shukla, S. Gupta and B. S. Awasthy, “A Phase II Study of Gemcitabine and Cisplatin in Chemotherapy-Naive, Unresectable Gall Bladder Cancer,” British Journal of Cancer, Vol. 90, No. 8, 2004, pp. 1516-1520. doi:10.1038/sj.bjc.6601736
[11] F. Giuliani, V. Gebbia, E. Maiello, N. Borsellino, E. Bajardi and G. Colucci, “Gemcitabine and Cisplatin for Inoperable and/or Metastatic Biliary Tree Carcinomas: A Multicenter Phase II Study of the Gruppo Oncologico dell’Italia Meridionale (GOIM),” Annals of Oncology, Vol. 17, No. 7, 2006, pp. 73-77. doi:10.1093/annonc/mdl956
[12] J. W. Valle, H. Wasan, P. Johnson, E. Jones, L. Dixon, R. Swindell, S. Baka, A. Maraveyas, P. Corrie, S. Falk, S. Gollins, F. Lofts, L. Evans, T. Meyer, A. Anthoney, T. Iveson, M. Highley, R. Osborne and J. Bridgewater, “Gemcitabine alone or in Combination with Cisplatin in Patients with Advanced or Metastatic Cholangiocarcinomas or Other Biliary Tract Tumours: A Multicentre Randomised Phase II Study: The UK ABC-01 Study,” British Journal of Cancer, Vol. 101, No. 4, 2009, pp. 621-627. doi:10.1038/sj.bjc.6605211
[13] J. Valle, H. Wasan, D. H. Palmer, D. Cunningham, A. Anthoney, A. Maraveyas, S. Madhusudan, T. Iveson, S. Hughes, S. P. Pereira, M. Roughton and J. Bridgewater, “Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer,” New England Journal of Medicine, Vol. 362, No. 14, 2010, pp. 1273-1281. doi:10.1056/NEJMoa0908721
[14] T. Okusaka, K. Nakachi, A. Fukutomi, N. Mizuno, S. Ohkawa, A. Funakoshi, M. Nagino, S. Kondo, S. Nagaoka, J. Funai, M. Koshiji, Y. Nambu, J. Furuse, M. Miyazaki and Y. Nimura, “Gemcitabine alone or in Combination with Cisplatin in Patients with Biliary Tract Cancer: A Comparative Multicentre Study in Japan,” British Journal of Cancer, Vol. 103, No. 4, 2010, pp. 469-474. doi:10.1038/sj.bjc.6605779
[15] D. Marino, F. Leone, G. Cavalloni, C. Cagnazzo and M. Aglietta, “Biliary Tract Carcinomas: From Chemotherapy to Targeted Therapy,” Critical Reviews in Oncology/Hematology, Vol. 85, No. 2, 2013, pp. 136-148. doi:10.1016/j.critrevonc.2012.06.006
[16] V. H. Phan, M. M. Moore, A. J. McLachlan, M. PiquetteMiller, H. Xu and S. J. Clarke, “Ethnic Differences in Drug Metabolism and Toxicity from Chemotherapy,” Expert Opinion on Drug Metabolism & Toxicology, Vol. 5, No. 3, 2009, pp. 243-257. doi:10.1517/17425250902800153
[17] F. Eckel and R. M. Schmid, “Chemotherapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials,” British Journal of Cancer, Vol. 96, 2007, pp. 896-902. doi:10.1038/sj.bjc.6603648
[18] H. S. Won, M. A. Lee, E. S. Chung, D. G. Kim, Y. K. You, T. H. Hong and I. S. Lee, “Comparison of Thymidine Phosphorylase Expression and Prognostic Factors in Gallbladder and Bile Duct Cancer,” BMC Cancer, Vol. 10, No. 1, 2010, p. 564. doi:10.1186/1471-2407-10-564
[19] W. R. Jarnagin, D. S. Klimstra, M. Hezel, M. Gonen, Y. Fong, K. Roggin, K. Cymes, R. P. De Matteo, M. D’Angelica, L. H. Blumgart and B. Singh, “Differential Cell Cycle-Regulatory Protein Expression in Biliary Tract Adenocarcinoma: Correlation with Anatomic Site, Pathologic Variables, and Clinical Outcome,” Journal of Clinical Oncology, Vol. 24, No. 7, 2006, pp. 1152-1160. doi:10.1200/JCO.2005.04.6631
[20] W. B. Kim, H. J. Han, H. J. Lee, S. S. Park, T. J. Song, H. K. Kim, S. O. Suh, Y. C. Kim and S. Y. Choi, “Expression and Clinical Significance of Cell Cycle Regulatory Proteins in Gallbladder and Extrahepatic Bile Duct Cancer,” Annals of Surgical Oncology, Vol. 16, No. 1, 2009, pp. 23-34. doi:10.1245/s10434-008-0182-x

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.